The Medicare Advantage (MA) landscape, a sector defined by intense competition and multi-billion-dollar bonus structures, is currently grappling with a significant administrative upheaval. In a move that highlights the growing friction between federal regulators and private insurers, the Centers for Medicare & Medicaid Services (CMS) has announced it will voluntarily recalculate the 2027 Quality Bonus Payment (QBP) ratings for a segment of MA contracts.
This decision follows a pivotal legal defeat in a Georgia federal court, where the presiding judge sided with Clover Health in a dispute over the methodology used to calculate star ratings. As CMS moves to adjust its metrics, the industry is left to navigate a precarious environment where billions in potential revenue hang in the balance, and the very foundation of the star ratings program faces unprecedented scrutiny.
The Genesis of the Conflict: Clover Health’s Legal Challenge
The current crisis originated in November when Clover Health, a technology-driven insurer and physician enablement company, filed suit against CMS. The impetus for the legal action was a significant dip in the star rating for Clover’s largest plan, which plummeted from 4 stars to 3.5 stars.
For an MA insurer, the difference between 3.5 and 4 stars is not merely cosmetic; it is a financial chasm. Clover estimated that this reduction resulted in a loss of approximately $120 million in bonus payments. In its complaint, Clover alleged that CMS had exceeded its statutory authority by including "improper measures" in the ratings calculation.
Specifically, Clover challenged 20 distinct measures, arguing that:
- Ten measures were based on data that CMS lacked the legal authority to collect.
- Ten measures were implemented by the agency without adhering to the proper federal rulemaking channels mandated by the Administrative Procedure Act.
In late May, a Georgia federal judge delivered a decisive ruling, agreeing with Clover’s assessment. The court ordered CMS to recalculate the insurer’s 3.5-star rating by stripping away the disputed measures. While the ruling was initially narrow in its application to Clover, its broader implications sent shockwaves through the industry.
A Chronology of the Ratings Dispute
The relationship between CMS and MA insurers has become increasingly adversarial as profit margins in the sector have tightened. The following timeline tracks the escalation of the star ratings controversy:
- Pre-2024: Mounting concerns from industry watchdogs regarding the effectiveness of the Quality Bonus Program (QBP), with research suggesting the star ratings system does little to improve actual clinical outcomes while inflating taxpayer costs.
- November 2024: Clover Health initiates litigation against CMS, challenging the inclusion of 20 questionable measures in its star rating calculation.
- May 2025: A federal judge in Georgia rules in favor of Clover Health, finding that CMS utilized unauthorized data and bypassed proper rulemaking procedures. The court orders a specific recalculation for Clover.
- June 2025: CMS issues a memo announcing a voluntary, industry-wide recalculation of 2027 QBP ratings, attempting to preempt further litigation while maintaining its stance on certain contested methodologies.
- Ongoing: Analysts and industry stakeholders monitor the situation, as insurers weigh the risk of individual lawsuits against the potential for administrative relief.
Supporting Data: The Financial Stakes of the Star Ratings
The importance of the 4-star threshold cannot be overstated. In the Medicare Advantage program, 4 stars is the "magic number" that triggers eligibility for significant bonus payments. Furthermore, these ratings determine the size of rebates provided to plans that submit bids below the CMS benchmark.
When analysts at TD Cowen examined the potential impact of applying the Clover Health court decision across the entire industry, the numbers were staggering. Had CMS been forced to extrapolate the judge’s ruling—removing all 20 contested measures—the financial windfall for major players would have been immense:
- UnitedHealthcare: Industry analysts estimated that the company’s average scores would have risen from 4.11 to 4.27, resulting in a potential financial benefit of roughly $500 million.
- Elevance Health: Calculations suggested an improvement in scores from 3.9 to 3.92, providing a $25 million boost to the company’s bottom line.
These figures illustrate why insurers are becoming increasingly litigious. With CMS cracking down on overpayments and facing pressure to reduce the $12.7 billion in annual bonus payouts (as estimated by KFF), the star ratings program has become the primary battleground for the financial viability of many MA plans.
Official Responses and Strategic Maneuvering
In its recent memorandum, CMS attempted to strike a balance between compliance with the court’s order and the preservation of its regulatory authority. The agency stated that it is recalculating ratings "in light of a recent court decision," but it is doing so selectively.
For Clover Health, CMS removed all 20 of the challenged measures. However, for the rest of the industry, the agency appears to be taking a more surgical approach. CMS is only removing measures related to data source authority—such as complaints against health plans, voluntary disenrollment rates, and the availability of foreign language interpreters for customer service.
Notably, CMS is not removing the 10 measures that Clover challenged on the grounds of improper rulemaking. According to TD Cowen analyst Molly Turco, this is a calculated signal: "It appears that CMS is essentially conceding on the data source argument and removing those challenged measures as well as unchallenged measures that could be vulnerable to a data source argument in a future lawsuit."
However, by retaining the measures challenged under rulemaking procedural grounds, CMS is effectively stating its intention to defend its regulatory process in future courts. The agency underscored this resolve by moving for the Georgia court to reconsider its ruling and leaving the door open for a formal appeal. "CMS’s decision to recalculate 2027 QBP ratings as described herein has no bearing on CMS’s potential exercise of its right to appeal this decision," the agency noted.
Implications for the Medicare Advantage Market
The implications of this legal and administrative standoff are multifaceted, affecting regulators, insurers, and the broader healthcare system.
1. The Erosion of Regulatory Trust
For the third consecutive year, CMS has been forced to recalibrate payments due to successful legal challenges. This trend suggests a growing divide between federal regulators and the private entities they oversee. When the methodology of a multi-billion-dollar incentive program becomes the subject of constant litigation, the credibility of the entire program is weakened.
2. A New Avenue for Litigation
The CMS decision to offer a limited, voluntary recalculation may not be enough to satisfy insurers who feel they have been unfairly penalized. The move creates a new legal opening: insurers may now choose to sue CMS for failing to apply the full scope of the Georgia ruling, or they may wait until the final 2027 star ratings are released in October to determine if their specific contracts were adequately adjusted.
3. The Future of the Quality Bonus Program
Watchdogs have long argued that the QBP is fundamentally flawed. Research has frequently highlighted that star ratings are often decoupled from clinical quality. As taxpayer spending on Medicare Advantage continues to balloon—projected to reach $76 billion in overpayments by 2026—policymakers are under mounting pressure to reform the program. The recent court victory by Clover Health provides ammunition for those who argue that the star ratings system is an opaque, overly complex, and legally vulnerable mechanism that lacks a clear nexus to patient care improvements.
4. Operational Uncertainty for Payers
For MA insurers, the current environment is one of extreme volatility. Planning for the 2027 fiscal year requires certainty regarding revenue streams, yet the ongoing disputes over star ratings make budget forecasting a perilous task. The "jockeying" for higher scores is no longer just about clinical performance; it is now as much about legal strategy and regulatory maneuvering as it is about patient outcomes.
Conclusion
The standoff between CMS and the Medicare Advantage industry is far from resolved. While the agency has taken a step toward appeasement by recalculating certain star ratings, the retention of contentious rulemaking measures ensures that the legal battle is likely to persist.
As the October deadline for the 2027 star ratings approaches, the industry remains on high alert. The precedent set by the Clover Health case has undoubtedly shifted the power dynamic between regulators and private insurers, leaving both parties to prepare for a future where every decimal point in a star rating is treated as a high-stakes legal matter. Whether this will lead to a more transparent and effective quality program or simply more expensive litigation remains the defining question for the Medicare Advantage sector in the coming years.
